Kristin Abate - 13 May 2026 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Reporting relationship: Chief Accounting Officer
Issuer ticker: KPTI
Reported as of: 13 May 2026
Net transaction value: -$504
SEC form: 4
Accepted by SEC: 15 May 2026, 16:04:57 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Nancy Smith as Attorney-in-Fact for Kristin Abate

Key filing fact

Kristin Abate filed Form 4 for Karyopharm Therapeutics Inc. (KPTI) on 15 May 2026.

Key facts

This page summarizes Kristin Abate's Form 4 filing for Karyopharm Therapeutics Inc. (KPTI).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 15 May 2026, 16:04.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$504.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002045943 Primary reporting owner

Abate Kristin

Relationship: Chief Accounting Officer
Address: C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON
Signature: /s/ Nancy Smith as Attorney-in-Fact for Kristin Abate
Signature date: 15 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KPTI transaction

Common Stock

Award

Transaction value
Shares: +121
Change %: +0.51%
Price: $0.000000^*
Shares after: 23,854
Date: 13 May 2026
Ownership: Direct
Footnotes: F1, F2

KPTI transaction

Common Stock

Sale

Transaction value: $504
Shares: -53
Change %: -0.22%
Price: $9.50
Shares after: 23,801
Date: 14 May 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.

Footnote F2

Includes 1,670 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan, as amended, on April 30, 2026.

Footnote F3

This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.